Screening men for prostate cancer cut mortality rates by about half in a large study, researchers report. The screening test under investigation is called a prostate-specific antigen (PSA) test, which measures blood levels of a protein produced by prostate gland cells and is a marker for prostate cancer.
PSA is considered a controversial screening test because it can detect cancers that may not advance during a man’s natural life span, resulting in possible over-treatment and reduced quality of life. These latest findings, published in the July 1 issue of Lancet Oncology, could shed new light on the potential benefits of PSA screening…..
Last year, the American Urological Association recommended that men begin undergoing prostate cancer screening at age 40 instead of age 50, the group’s previous recommendation. This revision was criticized by some prostate cancer experts because of concerns that extensive screening would lead to over-diagnosis of the disease and create unnecessary anxiety among patients.